Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Evaluation of the Short-, Mid-, and Long-term Effects of Tofacitinib on Lymphocytes in Patients with Rheumatoid Arthritis.

van Vollenhoven R, Lee EB, Strengholt S, Mojcik C, Valdez H, Krishnaswami S, Biswas P, Lazariciu I, Hazra A, Clark JD, Hodge J, Wang L, Choy E.

Arthritis Rheumatol. 2018 Nov 14. doi: 10.1002/art.40780. [Epub ahead of print]

PMID:
30427585
2.

Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.

Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R.

Br J Dermatol. 2019 Jan;180(1):67-75. doi: 10.1111/bjd.17149. Epub 2018 Oct 10.

PMID:
30188571
3.

Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study.

Tanaka Y, Sugiyama N, Toyoizumi S, Lukic T, Lamba M, Zhang R, Chen C, Stock T, Valdez H, Mojcik C, Fan H, Deng C, Yuasa H.

Rheumatology (Oxford). 2019 Jan 1;58(1):70-79. doi: 10.1093/rheumatology/key250.

4.

Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis.

Ma G, Xie R, Strober B, Langley R, Ito K, Krishnaswami S, Wolk R, Valdez H, Rottinghaus S, Tallman A, Gupta P.

Clin Pharmacol Drug Dev. 2018 Aug;7(6):587-596. doi: 10.1002/cpdd.471. Epub 2018 Jun 1.

PMID:
29856518
5.

Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.

Valenzuela F, Korman NJ, Bissonnette R, Bakos N, Tsai TF, Harper MK, Ports WC, Tan H, Tallman A, Valdez H, Gardner AC.

Br J Dermatol. 2018 Oct;179(4):853-862. doi: 10.1111/bjd.16798. Epub 2018 Aug 13.

PMID:
29782642
6.

Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.

Fitz L, Zhang W, Soderstrom C, Fraser S, Lee J, Quazi A, Wolk R, Mebus CA, Valdez H, Berstein G.

Clin Exp Dermatol. 2018 Oct;43(7):790-797. doi: 10.1111/ced.13561. Epub 2018 May 10.

PMID:
29748971
7.

Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.

Dasic G, Jones T, Frajzyngier V, Rojo R, Madsen A, Valdez H.

Pharmacol Res Perspect. 2018 Feb;6(1). doi: 10.1002/prp2.371.

8.

T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment.

Winthrop KL, Korman N, Abramovits W, Rottinghaus ST, Tan H, Gardner A, Mukwaya G, Kaur M, Valdez H.

J Am Acad Dermatol. 2018 Jun;78(6):1149-1155.e1. doi: 10.1016/j.jaad.2017.09.076. Epub 2018 Mar 2.

PMID:
29080806
9.

Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.

Kim J, Tomalin L, Lee J, Fitz LJ, Berstein G, Correa-da Rosa J, Garcet S, Lowes MA, Valdez H, Wolk R, Suarez-Farinas M, Krueger JG.

J Invest Dermatol. 2018 Feb;138(2):273-281. doi: 10.1016/j.jid.2017.08.040. Epub 2017 Sep 18.

PMID:
28927890
10.

A recombinant iron transport protein from Bordetella pertussis confers protection against Bordetella parapertussis.

Alvarez Hayes J, Oviedo JM, Valdez H, Laborde JM, Maschi F, Ayala M, Shah R, Fernandez Lahore M, Rodriguez ME.

Microbiol Immunol. 2017 Oct;61(10):407-415. doi: 10.1111/1348-0421.12532. Epub 2017 Sep 26.

PMID:
28857261
11.

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.

Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, Hirose T, Nduaka CI, Wang L, Mendelsohn AM, Fan H, Chen C, Bananis E.

Arthritis Rheumatol. 2017 Oct;69(10):1960-1968. doi: 10.1002/art.40189. Epub 2017 Sep 6.

12.

Herpes zoster in psoriasis patients treated with tofacitinib.

Winthrop KL, Lebwohl M, Cohen AD, Weinberg JM, Tyring SK, Rottinghaus ST, Gupta P, Ito K, Tan H, Kaur M, Egeberg A, Mallbris L, Valdez H.

J Am Acad Dermatol. 2017 Aug;77(2):302-309. doi: 10.1016/j.jaad.2017.03.023.

PMID:
28711084
13.

Ultra-Sensitive Measurement of IL-17A and IL-17F in Psoriasis Patient Serum and Skin.

Soderstrom C, Berstein G, Zhang W, Valdez H, Fitz L, Kuhn M, Fraser S.

AAPS J. 2017 Jul;19(4):1218-1222. doi: 10.1208/s12248-017-0094-4. Epub 2017 May 22.

PMID:
28534291
14.

Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21. Review.

15.

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.

Hutmacher MM, Papp K, Krishnaswami S, Ito K, Tan H, Wolk R, Valdez H, Mebus C, Rottinghaus ST, Gupta P.

CPT Pharmacometrics Syst Pharmacol. 2017 May;6(5):322-330. doi: 10.1002/psp4.12182. Epub 2017 Mar 20.

16.

The targeting of starch binding domains from starch synthase III to the cell wall alters cell wall composition and properties.

Grisolia MJ, Peralta DA, Valdez HA, Barchiesi J, Gomez-Casati DF, Busi MV.

Plant Mol Biol. 2017 Jan;93(1-2):121-135. doi: 10.1007/s11103-016-0551-y. Epub 2016 Oct 21.

PMID:
27770231
17.

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.

Valenzuela F, Paul C, Mallbris L, Tan H, Papacharalambous J, Valdez H, Mamolo C.

J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1753-1759. doi: 10.1111/jdv.13702. Epub 2016 Jun 7.

18.

Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.

Feldman SR, Thaçi D, Gooderham M, Augustin M, de la Cruz C, Mallbris L, Buonanno M, Tatulych S, Kaur M, Lan S, Valdez H, Mamolo C.

J Am Acad Dermatol. 2016 Dec;75(6):1162-1170.e3. doi: 10.1016/j.jaad.2016.07.040. Epub 2016 Sep 28.

PMID:
27692733
19.

Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.

Tan H, Valdez H, Griffins CE, Mrowietz U, Tallman A, Wolk R, Gordon K.

J Dermatolog Treat. 2017 Feb;28(1):3-7. doi: 10.1080/09546634.2016.1214671. Epub 2016 Aug 18. Erratum in: J Dermatolog Treat. 2017 Feb;28(1):x.

PMID:
27538247
20.

Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.

Wu JJ, Strober BE, Hansen PR, Ahlehoff O, Egeberg A, Qureshi AA, Robertson D, Valdez H, Tan H, Wolk R.

J Am Acad Dermatol. 2016 Nov;75(5):897-905. doi: 10.1016/j.jaad.2016.06.012. Epub 2016 Aug 4.

PMID:
27498960
21.

Bordetella pertussis modulates human macrophage defense gene expression.

Valdez HA, Oviedo JM, Gorgojo JP, Lamberti Y, Rodriguez ME.

Pathog Dis. 2016 Aug;74(6). pii: ftw073. doi: 10.1093/femspd/ftw073. Epub 2016 Jul 26.

PMID:
27465637
22.

Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.

Menter MA, Papp KA, Cather J, Leonardi C, Pariser DM, Krueger JG, Wohlrab J, Amaya-Guerra M, Kaszuba A, Nadashkevich O, Tsai TF, Gupta P, Tan H, Valdez H, Mallbris L, Tatulych S.

J Drugs Dermatol. 2016 May 1;15(5):568-80.

PMID:
27168266
23.

Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.

Krueger J, Clark JD, Suárez-Fariñas M, Fuentes-Duculan J, Cueto I, Wang CQ, Tan H, Wolk R, Rottinghaus ST, Whitley MZ, Valdez H, von Schack D, O'Neil SP, Reddy PS, Tatulych S; A3921147 Study Investigators.

J Allergy Clin Immunol. 2016 Apr;137(4):1079-1090. doi: 10.1016/j.jaci.2015.12.1318.

24.

Proteome analysis of Bordetella pertussis isolated from human macrophages.

Lamberti Y, Cafiero JH, Surmann K, Valdez H, Holubova J, Večerek B, Sebo P, Schmidt F, Völker U, Rodriguez ME.

J Proteomics. 2016 Mar 16;136:55-67. doi: 10.1016/j.jprot.2016.02.002. Epub 2016 Feb 10.

PMID:
26873878
25.

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.

Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, Kwok K, Lukic T, Mortensen E, Ponce de Leon D, Riese R, Valdez H.

Ann Rheum Dis. 2016 Jun;75(6):1133-8. doi: 10.1136/annrheumdis-2015-207319. Epub 2015 Aug 28. Review.

26.

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R; OPT Compare Investigators.

Lancet. 2015 Aug 8;386(9993):552-61. doi: 10.1016/S0140-6736(14)62113-9. Epub 2015 Jun 4.

PMID:
26051365
27.

One Egg per Day Improves Inflammation when Compared to an Oatmeal-Based Breakfast without Increasing Other Cardiometabolic Risk Factors in Diabetic Patients.

Ballesteros MN, Valenzuela F, Robles AE, Artalejo E, Aguilar D, Andersen CJ, Valdez H, Fernandez ML.

Nutrients. 2015 May 11;7(5):3449-63. doi: 10.3390/nu7053449.

28.

Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.

Valenzuela F, Papp KA, Pariser D, Tyring SK, Wolk R, Buonanno M, Wang J, Tan H, Valdez H.

BMC Dermatol. 2015 May 8;15:8. doi: 10.1186/s12895-015-0025-y.

29.

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.

Surdo M, Alteri C, Puertas MC, Saccomandi P, Parrotta L, Swenson L, Chapman D, Costa G, Artese A, Balestra E, Aquaro S, Alcaro S, Lewis M, Clotet B, Harrigan R, Valdez H, Svicher V, Perno CF, Martinez-Picado J, Ceccherini-Silberstein F.

Clin Microbiol Infect. 2015 Jan;21(1):103.e1-6. doi: 10.1016/j.cmi.2014.08.002. Epub 2014 Oct 29.

30.

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.

Bissonnette R, Iversen L, Sofen H, Griffiths CE, Foley P, Romiti R, Bachinsky M, Rottinghaus ST, Tan H, Proulx J, Valdez H, Gupta P, Mallbris L, Wolk R.

Br J Dermatol. 2015;172(5):1395-406. doi: 10.1111/bjd.13551. Epub 2015 Apr 2.

PMID:
25418186
31.

Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.

Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Soma K, Nduaka CI, Kwok K, Valdez H, Benda B, Riese R.

Arthritis Rheumatol. 2014 Nov;66(11):2924-37. doi: 10.1002/art.38779.

32.

Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.

Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, Kawabata T, Riese R.

Arthritis Rheumatol. 2014 Oct;66(10):2675-84. doi: 10.1002/art.38745.

33.

Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.

Swenson LC, Chui CK, Brumme CJ, Chan D, Woods CK, Mo T, Dong W, Chapman D, Lewis M, Demarest JF, James I, Portsmouth S, Goodrich J, Heera J, Valdez H, Harrigan PR.

Antimicrob Agents Chemother. 2013 Dec;57(12):6122-30. doi: 10.1128/AAC.01534-13. Epub 2013 Sep 30.

34.

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.

Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R, Valdez H, Langley RG, Harness J, Menter A, Papp K.

Br J Dermatol. 2013 Nov;169(5):992-9. doi: 10.1111/bjd.12517.

PMID:
23855761
35.

Improving the glycosyltransferase activity of Agrobacterium tumefaciens glycogen synthase by fusion of N-terminal starch binding domains (SBDs).

Martín M, Wayllace NZ, Valdez HA, Gomez-Casati DF, Busi MV.

Biochimie. 2013 Oct;95(10):1865-70. doi: 10.1016/j.biochi.2013.06.009. Epub 2013 Jun 21.

PMID:
23796574
36.

Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.

Swenson LC, Dong WW, Mo T, Demarest J, Chapman D, Ellery S, Heera J, Valdez H, Poon AF, Harrigan PR.

Clin Infect Dis. 2013 Jun;56(11):1659-66. doi: 10.1093/cid/cit105. Epub 2013 Feb 21.

PMID:
23429552
37.

Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes.

Lee GQ, Harrigan PR, Dong W, Poon AF, Heera J, Demarest J, Rinehart A, Chapman D, Valdez H, Portsmouth S.

AIDS Res Hum Retroviruses. 2013 Jun;29(6):979-84. doi: 10.1089/AID.2012.0338. Epub 2013 Mar 6.

38.

Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.

Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA, Kaplan R, Lazzarin A, Valdez H, Goodrich J, Mori J, Craig C, Tawadrous M.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):171-9. doi: 10.1097/QAI.0b013e31827a2ba2..

PMID:
23328090
39.

Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.

Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, Valluri SR, Craig C, McFadyen L, Vourvahis M, Heera J, Valdez H, Rinehart AR, Portsmouth S.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):164-70. doi: 10.1097/QAI.0b013e31827b51b5.

PMID:
23187936
40.

Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078.

Portsmouth S, Valluri SR, Däumer M, Thiele B, Valdez H, Lewis M, Craig C, Thielen A, James I, Demarest J, Heera J.

Antiviral Res. 2013 Jan;97(1):60-5. doi: 10.1016/j.antiviral.2012.11.002. Epub 2012 Nov 16.

PMID:
23165088
41.

Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.

McGovern RA, Thielen A, Portsmouth S, Mo T, Dong W, Woods CK, Zhong X, Brumme CJ, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):279-86. doi: 10.1097/QAI.0b013e31826249cf.

PMID:
23095934
42.
43.

HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease.

Shive CL, Biancotto A, Funderburg NT, Pilch-Cooper HA, Valdez H, Margolis L, Sieg SF, McComsey GA, Rodriguez B, Lederman MM.

J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):145-52.

44.

Ultra-high pressure LC determination of glucosamine in shrimp by-products and migration tests of chitosan films.

Sanches-Silva A, Ribeiro T, Albuquerque TG, Paseiro P, Sendón R, de Quirós AB, López-Cervantes J, Sánchez-Machado DI, Valdez HS, Angulo I, Aurrekoetxea GP, Costa HS.

J Sep Sci. 2012 Mar;35(5-6):633-40. doi: 10.1002/jssc.201100855.

PMID:
22517638
45.

Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Thielen A, Jensen MA, Knapp DJ, Chapman D, Portsmouth S, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

Clin Infect Dis. 2011 Oct;53(7):732-42. doi: 10.1093/cid/cir493.

PMID:
21890778
46.

Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy.

Butler SL, Valdez H, Westby M, Perros M, June CH, Jacobson JM, Levy Y, Cooper DA, Douek D, Lederman MM, Tebas P.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):297-303. doi: 10.1097/QAI.0b013e31822ccfcc. Review.

PMID:
21792065
47.

An enzyme-coupled continuous spectrophotometric assay for glycogen synthases.

Wayllace NZ, Valdez HA, Merás A, Ugalde RA, Busi MV, Gomez-Casati DF.

Mol Biol Rep. 2012 Jan;39(1):585-91. doi: 10.1007/s11033-011-0774-6. Epub 2011 May 17.

PMID:
21584701
48.

Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.

Schapiro JM, Boucher CA, Kuritzkes DR, van de Vijver DA, Llibre JM, Lewis M, Simpson P, Delogne C, McFadyen L, Chapman D, Perros M, Valdez H, van der Ryst E, Westby M.

Antivir Ther. 2011;16(3):395-404. doi: 10.3851/IMP1759.

PMID:
21555822
49.

Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially.

Thielen A, Lengauer T, Swenson LC, Dong WW, McGovern RA, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

Antivir Ther. 2011;16(3):319-28. doi: 10.3851/IMP1769.

PMID:
21555814
50.

America's sons and daughters.

Valdez HL.

Int J Emerg Ment Health. 2010 Summer;12(3):213-5. No abstract available.

PMID:
21473372

Supplemental Content

Loading ...
Support Center